{"info": {"address1": "251 Ballardvale Street", "city": "Wilmington", "state": "MA", "zip": "01887", "country": "United States", "phone": "781 222 6000", "website": "https://www.criver.com", "industry": "Diagnostics & Research", "sector": "Healthcare", "longBusinessSummary": "Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.", "fullTimeEmployees": 20000, "companyOfficers": [{"maxAge": 1, "name": "Mr. James C. Foster J.D.", "age": 71, "title": "Chairman, CEO & Pres", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": 2507989, "exercisedValue": 6133567, "unexercisedValue": 366263}, {"maxAge": 1, "name": "Ms. Flavia H. Pease", "age": 49, "title": "Corp. Exec. VP & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 772398, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Birgit  Girshick", "age": 52, "title": "Corp. Exec. VP & COO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 1151230, "exercisedValue": 0, "unexercisedValue": 688829}, {"maxAge": 1, "name": "Mr. Joseph W. LaPlume", "age": 48, "title": "Corp. Exec. VP of Corp. Devel. & Strategy", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 871346, "exercisedValue": 887843, "unexercisedValue": 573403}, {"maxAge": 1, "name": "Mr. William D. Barbo", "age": 61, "title": "Chief Commercial Officer & Corp. Exec. VP", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 928549, "exercisedValue": 354379, "unexercisedValue": 259644}, {"maxAge": 1, "name": "Mr. Michael Gunnar Knell", "age": 45, "title": "Corp. Sr. VP & Chief Accounting Officer", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Julie  Frearson Ph.D.", "title": "Corp. Sr. VP & Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Mintz", "title": "Corp. Sr. VP & Chief Information Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Todd  Spencer", "title": "Corp. VP of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew L. Daniel", "title": "Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 208.55, "open": 210.05, "dayLow": 205.491, "dayHigh": 210.05, "regularMarketPreviousClose": 208.55, "regularMarketOpen": 210.05, "regularMarketDayLow": 205.491, "regularMarketDayHigh": 210.05, "payoutRatio": 0.0, "beta": 1.343944, "trailingPE": 21.940361, "forwardPE": 16.8317, "volume": 404168, "regularMarketVolume": 404168, "averageVolume": 558126, "averageVolume10days": 385640, "averageDailyVolume10Day": 385640, "bid": 0.0, "ask": 207.6, "bidSize": 800, "askSize": 1300, "marketCap": 10544475136, "fiftyTwoWeekLow": 181.36, "fiftyTwoWeekHigh": 301.1, "priceToSalesTrailing12Months": 2.6519911, "fiftyDayAverage": 215.9314, "twoHundredDayAverage": 219.21304, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 13346021376, "profitMargins": 0.12229, "floatShares": 50399703, "sharesOutstanding": 51181800, "sharesShort": 1353976, "sharesShortPriorMonth": 1311416, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.026500002, "heldPercentInsiders": 0.00978, "heldPercentInstitutions": 0.98663, "shortRatio": 2.32, "shortPercentOfFloat": 0.030299999, "impliedSharesOutstanding": 0, "bookValue": 58.423, "priceToBook": 3.526351, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 0.362, "netIncomeToCommon": 486225984, "trailingEps": 9.39, "forwardEps": 12.24, "pegRatio": 2.13, "enterpriseToRevenue": 3.357, "enterpriseToEbitda": 13.867, "52WeekChange": -0.30597943, "SandP52WeekChange": -0.06829989, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "CRL", "underlyingSymbol": "CRL", "shortName": "Charles River Laboratories Inte", "longName": "Charles River Laboratories International, Inc.", "firstTradeDateEpochUtc": 961767000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3967529a-ede8-32eb-b408-a3032696a9fe", "messageBoardId": "finmb_91093", "gmtOffSetMilliseconds": -14400000, "currentPrice": 206.02, "targetHighPrice": 290.0, "targetLowPrice": 203.0, "targetMeanPrice": 252.58, "targetMedianPrice": 257.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 233912000, "totalCashPerShare": 4.588, "ebitda": 962403968, "totalDebt": 3147479040, "quickRatio": 0.904, "currentRatio": 1.318, "totalRevenue": 3976059904, "debtToEquity": 104.1, "revenuePerShare": 78.25, "returnOnAssets": 0.05628, "returnOnEquity": 0.17544001, "grossProfits": 1462651000, "freeCashflow": 299300864, "operatingCashflow": 619640000, "earningsGrowth": 0.366, "revenueGrowth": 0.215, "grossMargins": 0.36786, "ebitdaMargins": 0.24204999, "operatingMargins": 0.16562, "financialCurrency": "USD", "trailingPegRatio": 1.2632}, "news": [{"uuid": "c040e1f8-8285-39b9-a42a-3e1181a2dc37", "title": "Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/charles-river-laboratories-schedules-first-123000130.html", "providerPublishTime": 1681216200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/8x40OQQfCWYn5d.q9yMPxA--~B/aD0xMjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e15af413ee8ea550cc9702a1062bfaa3", "width": 480, "height": 126, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/3pLkQRqOhw6GE.PqXCQH3g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e15af413ee8ea550cc9702a1062bfaa3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "a4f426a6-a348-346e-87af-0c7731640b22", "title": "Charles River Laboratories Showcases End-to-End Oncology Capabilities at AACR 2023", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/charles-river-laboratories-showcases-end-120000905.html", "providerPublishTime": 1681128000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/6cDrOBAJ6iF74_53GJjwTA--~B/aD0xMjY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bdd765561baa17f560f509d7c52f0e13", "width": 480, "height": 126, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OkHcNz7Kzk.goh6nIdZjVg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bdd765561baa17f560f509d7c52f0e13", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "1120eab9-1ef4-3513-a534-a77da4d9ef7c", "title": "Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/calculating-fair-value-charles-river-125953420.html", "providerPublishTime": 1681045193, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "fc611704-36ec-329e-ab9a-29ecceaefc27", "title": "Charles Rivers recommends against PETA's proposal for transparency on lab monkeys", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/charles-rivers-recommends-against-petas-120259674.html", "providerPublishTime": 1680264179, "type": "STORY", "relatedTickers": ["CRL"]}, {"uuid": "e2e82e11-dfc6-3adb-bb10-8e5ba377b95d", "title": "Why Is Charles River (CRL) Down 14.8% Since Last Earnings Report?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/why-charles-river-crl-down-153003200.html", "providerPublishTime": 1679671803, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2", "width": 900, "height": 469, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/0VAyjhJrJObsyjxSwVSkjQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "356e178b-fe8c-3486-93b8-3c1311550712", "title": "The total return for Charles River Laboratories International (NYSE:CRL) investors has risen faster than earnings growth over the last five years", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/total-return-charles-river-laboratories-113032999.html", "providerPublishTime": 1678966232, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "cbab0b8f-df97-36d3-b1f6-537d42dfbac2", "title": "Charles River's (CRL) New Cloud Platform Offers Real-Time Data", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/charles-rivers-crl-cloud-platform-191407418.html", "providerPublishTime": 1678907647, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6ApVM73LAs1faE7RVKKaLQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL", "KERN", "HAE"]}, {"uuid": "4aff1f7c-d967-3abc-855c-d73a2975b6cf", "title": "Charles River (CRL) Advances CDMO Portfolio With Latest Offer", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/charles-river-crl-advances-cdmo-122812980.html", "providerPublishTime": 1678796892, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fjS8E3eMtYWm5omrejEHog--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c7d7c00f4e1e615cc981c95227b4d9a3", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EWtCyWv3a7VQmS.EMZiCsg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/c7d7c00f4e1e615cc981c95227b4d9a3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL", "HAE", "KERN"]}]}